News from helsinn healthcare sa A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

13 Oct, 2014, 13:40 BST FDA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV Helsinn Group and Eisai Inc. announced today that the Food and Drug...


26 Jun, 2014, 13:46 BST Eisai Oncology & Helsinn Group to Present New CINV Research at 2014 International Symposium on Supportive Care in Cancer

Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed-dose...


01 Apr, 2014, 13:20 BST Helsinn Promotes the use of Mobile Technology in Cancer Supportive Care Through Mobile Health

 The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated...


13 Mar, 2014, 13:00 GMT Helsinn Named as One of the Best Places to Work in New Jersey by NJBIZ

Helsinn Group, the company focused on building quality cancer care, is pleased to announce today that its U.S. subsidiary, Helsinn Therapeutics...


29 Jan, 2014, 11:00 GMT Helsinn Announces European Medicines Agency Acceptance of Regulatory Submission for Netupitant-palonosetron Fixed Dose Combination (NEPA)

NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced...


15 Jan, 2014, 13:12 GMT Helsinn Group and Angelini Ink an Agreement for License Rights to Phase-III Ghrelin Receptor Agonist Anamorelin in Central & Eastern Europe

Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for...


19 Dec, 2013, 07:00 GMT Swiss-based Helsinn Group and Mundipharma Sign for Rights to Phase III Netupitant-Palonosetron Fixed Dose Combination for China

The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and...


18 Dec, 2013, 12:32 GMT Helsinn and Italfarmaco Reinforce Their Alliance Through the Grant of Rights to Phase-III Ghrelin Receptor Agonist Anamorelin in Italy

Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development...


09 Dec, 2013, 16:33 GMT Helsinn Group and Eisai Announce FDA Acceptance of New Drug Application for Investigational Compound Netupitant 300 mg + Palonosetron 0.50 mg (NEPA)

Seeking indication for prevention of chemotherapy-induced nausea and vomiting Helsinn Group and Eisai Inc. today announced that the U.S. Food and...


12 Nov, 2013, 03:00 GMT Helsinn and Chugai Pharma Marketing Enter into Agreement for Rights of Anamorelin, Currently in Development for Treatment of Anorexia-Cachexia Syndrome Related to Non-small Cell Lung Cancer in top EU Markets

Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its...


09 Jul, 2013, 14:00 BST Helsinn and Advancell Sign a Partnering Agreement for ATH008, a New Compound for Chemotherapy-Induced Dermatological Injuries

The Swiss pharmaceutical group Helsinn and the Spanish company, Advancell, Advanced In Vitro Cell Technologies, SA, today announced a partnering...


28 May, 2013, 12:35 BST Helsinn and Zealand announce Helsinn's decision to advance the development of elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea

The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study...


16 May, 2013, 07:00 BST Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting

Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) Helsinn Group and Eisai Inc. announced today top-line...


16 May, 2013, 06:00 BST Helsinn and Vifor Pharma Sign Licensing and Distribution Agreement for Netupitant-Palonosetron Fixed Dose Combination

Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for...


22 Apr, 2013, 13:30 BST Helsinn and DARA Announce U.S. Launch of Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis

The Swiss pharmaceutical Helsinn Group, a leading player in the cancer supportive care arena, announced today that DARA BioSciences, Inc., a U.S....


03 Apr, 2013, 13:30 BST Helsinn Group Enters into a New Partnership with Healthcare Businesswomen's Association (HBA)

Helsinn Group has entered into a new partnership with Healthcare Businesswomen's Association (HBA). HBA is the premier catalyst for the leadership...


29 Jan, 2013, 13:00 GMT Helsinn Grants Stendhal Rights to Anamorelin, a First-In-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)

Stendhal strengthens its pipeline of in-licensed specialty drug products by signing a Distribution and License Agreement with Helsinn Group for an...


13 Nov, 2012, 18:31 GMT Helsinn Group, Switzerland Announces Support of CancerLinQ™

A Rapid Learning System in Oncology Funded by the Conquer Cancer Foundation of the American Society of Clinical Oncology Helsinn Group announces that ...


15 Oct, 2012, 07:00 BST Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)

Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a Distribution and License Agreement...


01 Oct, 2012, 12:39 BST Oral Palonosetron Shows Safe and Effective Control of Nausea and Vomiting Induced by Multiple Cycles of Chemotherapy

New data presented at the 2012 meeting of the European Society of Medical Oncology (ESMO) in Vienna show antiemetic efficacy maintained across the...


24 Sep, 2012, 10:20 BST Helsinn Group, Switzerland Announces a License Agreement for netupitant - palonosetron Fixed Dose Combination With CJ CheilJedang, South Korea for Korea

Helsinn Group announces that on September 18th it has signed a license agreement with CJ CheilJedang, Korea for Helsinn's new product for potential...


13 Sep, 2012, 14:56 BST Helsinn Grants to DARA Exclusive U.S. Commercial Rights to Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis

Gelclair® Strengthens DARA's Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products The Helsinn Group of Switzerland...


16 Jul, 2012, 11:00 BST Helsinn Partners With the European School Of Oncology (ESO)

Starting July 1stthe Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme Through its support to the Sharing...


27 Sep, 2011, 11:52 BST Helsinn and Riemser Extend Relationship in Germany

License Agreement for Germany on New Therapy in Development for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) Helsinn Healthcare...


26 Sep, 2011, 14:03 BST Helsinn Group is Reinforcing its Cancer Supportive Care Pipeline

The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated...